This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2020 May;21(3):e169-e170.

doi: 10.1016/j.cllc.2019.10.009. Epub 2019 Nov 6.

Lower Survival in Patients Who Develop Pneumonitis Following Immunotherapy for Lung Cancer

Karthik Suresh¹, Jarushka Naidoo²

Affiliations

Affiliations

¹ Division of Pulmonary/Critical Care, Johns Hopkins University School of Medicine, Baltimore, MD.
² Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD.

PMID: 31787546
DOI: 10.1016/j.cllc.2019.10.009

Comment

Lower Survival in Patients Who Develop Pneumonitis Following Immunotherapy for Lung Cancer

Karthik Suresh et al. Clin Lung Cancer. 2020 May.

. 2020 May;21(3):e169-e170.

doi: 10.1016/j.cllc.2019.10.009. Epub 2019 Nov 6.

Authors

Karthik Suresh¹, Jarushka Naidoo²

Affiliations

¹ Division of Pulmonary/Critical Care, Johns Hopkins University School of Medicine, Baltimore, MD.
² Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD.

PMID: 31787546
DOI: 10.1016/j.cllc.2019.10.009

No abstract available

PubMed Disclaimer

Comment in

Reply to "Prognostic Impact and Risk Factors of Immune-Related Pneumonitis in Patients With Non-Small-Cell Lung Cancer Who Received Programmed Death-1 Inhibitors".
Fukihara J, Sakamoto K, Koyama J, Ito T, Iwano S, Morise M, Ogawa M, Kondoh Y, Kimura T, Hashimoto N, Hasegawa Y. Fukihara J, et al. Clin Lung Cancer. 2020 May;21(3):e205. doi: 10.1016/j.cllc.2019.11.013. Epub 2019 Dec 2. Clin Lung Cancer. 2020. PMID: 31874731 No abstract available.

Comment on

Prognostic Impact and Risk Factors of Immune-Related Pneumonitis in Patients With Non-Small-Cell Lung Cancer Who Received Programmed Death 1 Inhibitors.
Fukihara J, Sakamoto K, Koyama J, Ito T, Iwano S, Morise M, Ogawa M, Kondoh Y, Kimura T, Hashimoto N, Hasegawa Y. Fukihara J, et al. Clin Lung Cancer. 2019 Nov;20(6):442-450.e4. doi: 10.1016/j.cllc.2019.07.006. Epub 2019 Aug 1. Clin Lung Cancer. 2019. PMID: 31446020

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information